ClinicalTrials.gg
CompletedNCT02962895Updated Jan 7, 2025Results posted

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

A Phase 2 interventional study of VAY736 and Placebo in Primary Sjogren Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 56 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
9th of 14
190 · median 240
Started
2017
the only one that year
Phase 2
9 of 15
1 open now
Registered
3rd of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2017, is one of 9 in phase 2, and was the 3rd registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Read the detailed description

This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group trial that was divided into 4 study periods.

Period 1: A screening period of 4 weeks to assess patient eligibility. Patients could be re-screened only once, and no study-related re-screening procedure could be performed prior to written re-consent by the patient.

Period 2: A blinded treatment period of 24 weeks. At baseline, eligible patients were randomized to one of three ianalumab dose arms (VAY736 5 mg, 50 mg or 300 mg s.c.) or a placebo arm (placebo s.c.). Blinded study drug was administered every four weeks (q4w) for a 24-week period.

Except for Japan, randomization was stratified by baseline ESSDAI score (\<10 or ≥10 based on weighted scores). Separate blocks of randomization numbers were generated for patients in Japan versus the other countries participating to ensure that Japanese patients were equally distributed across all treatment groups in the study.

The primary endpoint was assessed at the end of Period 2 (Week 24). Treatment assignment in Period 2 remained double-blinded until the end of Period 3.

Period 3: An extended blinded treatment period of 28 weeks. After Week 24 assessments, patients in the ianalumab 300 mg arm were re-randomized in a 1:1 ratio to either continue on ianalumab 300 mg s.c. q4w or switch to matching placebo up to Week 52. Patients who received placebo during Period 2 were switched to ianalumab 150 mg s.c q4w up to Week 52. Patients who received 5 mg and 50 mg s.c. in Period 2 proceeded directly to safety follow-up (Period 4). Treatment assignment in Period 3 remained double-blinded.

Period 4: A post-treatment safety follow-up period. Patients who prematurely discontinued the study treatment at any time point or completed the treatment as planned entered the safety follow-up period. The minimum required duration of follow-up in the study was 20 weeks from the last administration of the study treatment (mandatory follow-up). The maximum duration of the follow-up was 2 years from the last dose of the study treatment, and it was defined by the level of recovery of CD19+ B-cells: conditional follow up (with reduced visit frequency) until CD19+ B-cell levels return to at least 80% of baseline or 50 cells/µL, whichever occurred first. Patients who had not yet recovered their B-cell counts two years after last ianalumab dosing were discharged from the study and had undergone their End of Study (EoS) visit. Patients who were treated with another immunomodulatory or immunosuppressive treatment (e.g., azathioprine, cyclophosphamide, high dose glucocorticosteroids) after completion of the minimum 20-week safety follow-up period were excluded from further safety follow-up.

03

Conditions studied

  • Primary Sjogren Syndrome

Browse trials for

Keywords

  • Sjogren
  • VAY736
  • ianalumab
  • pSS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfilled revised American European Consensus Group criteria for pSS
  • Seropositive at screening for anti-Ro/SSA antibodies
  • Screening ESSDAI value >=6 scored from 7 domains: articular, cutaneous, glandular, lymphoadenopathy, constitutional, biologic and hematologic.

Exclusion criteria

Exclusion Criteria:

  • Secondary Sjogren's syndrome
  • Use of other drugs
  • Active viral, bacterial or other infections
  • Positive , , or tuberculosis test results at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    VAY736 dose 1 - 5mg

    VAY736 low

    Biological: VAY736

  • Experimental
    VAY736 dose 2 - 50mg

    VAY736 medium

    Biological: VAY736

  • Experimental
    VAY736 dose 3 - 300 mg

    VAY736 high

    Biological: VAY736

  • Placebo comparator
    Placebo

    Placebo control

    Other: Placebo

Interventions

  • BiologicalVAY736

    VAY736

    Also known as: Ianalumab

  • OtherPlacebo

    Placebo control

06

What researchers measure

Primary outcomes

  1. Least Squares Mean Change From Baseline in ESSDAI Score at Week 24

    The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Least Squares Mean Change From Baseline in ESSDAI Score at Weeks 4, 8, 12, and 16

    The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  2. Least Squares Mean Change From Baseline in ESSPRI Score at Week 24

    The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.

    Time frame: Baseline, Week 24

  3. Least Squares Mean Change From Baseline in ESSPRI Score at Weeks 4, 8, 12 and 16

    The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16

  4. Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks

    The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.

    Time frame: Baseline, Week 24

  5. Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score at Weeks 4, 8, 12 and 16

    The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.

    Time frame: Baseline, Weeks 4, 8, 12 and 16

  6. Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) Over 24 Weeks

    The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).

    Time frame: Baseline, Week 24

  7. Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) at Weeks 4, 8, 12 and 16

    The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).

    Time frame: Baseline, Weeks 4, 8, 12 and 16

  8. Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks

    Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.

    Time frame: Baseline, 24 weeks

  9. Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) at Weeks 4, 8, 12 and 16

    Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.

    Time frame: Baseline, Weeks 4, 8, 12 and 16

  10. Patient's Global Assessment (PaGA) Score at Weeks 4, 8, 12, 16 and 24

    The PaGA of disease activity was performed using a 100 mm Visual Analog Scale (VAS) ranging from 0 (no disease activity) to 100 (maximal disease activity), in response to the question "Considering all the ways Sjögren's syndrome affects you, please draw a line on the scale to indicate how well you are doing today". A negative change from baseline is a favourable outcome.

    Time frame: Weeks 4, 8, 12, 16 and 24

  11. Least Squares Mean Change From Baseline in Salivary Flow Rate at Week 24

    Change from baseline in salivary flow rate (unstimulated and stimulated) at 24 weeks as compared to placebo. Unstimulated saliva is a mix of serous and mucous secretions coming primarily from the submandibular and minor salivary glands. The parotid gland produces the largest volume of stimulated saliva. Stimulated saliva accounts for 80-90% of daily salivary production.

    Time frame: Baseline, 24 weeks

  12. Percent Change From Baseline in Whole Blood CD19+ B-cell Counts.

    B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.

    Time frame: Baseline, Week 24, Week 28

  13. Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts

    B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.

    Time frame: Up to two years from last dose patient received.

  14. Peak Serum Concentration of VAY736

    Pharmacokinetic Concentrations This outcome only applies to patients who received at least one dose of VAY739 (so not applicable to placebo)

    Time frame: baseline to week 24, then week 28

07

Results

Posted Oct 29, 2024

Participant flow

190 Patients were enrolled from 56 centers in 19 countries.

Period 2 (Randomized Set: Up to Week 24)
Participant flow — Period 2 (Randomized Set: Up to Week 24)
MilestonePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)VAY736 - 150 mgVAY736 300 mg - PlaceboVAY736 300 mg - VAY736 300 mg
Started49474747000
Completed47424346000
Not completed2541000
Withdrew: Withdrawal by subject1120000
Withdrew: Withdrawal of informed consent0100000
Withdrew: Adverse event0220000
Withdrew: New therapy for indication1000000
Withdrew: Non-compliance with treatment0100000
Withdrew: Pregnancy0001000
Period 3 (Randomized Set / Weeks: 24-52)
Participant flow — Period 3 (Randomized Set / Weeks: 24-52)
MilestonePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)VAY736 - 150 mgVAY736 300 mg - PlaceboVAY736 300 mg - VAY736 300 mg
Started0000472221
Completed0000422217
Not completed0000504
Withdrew: Patient/guardian decision0000001
Withdrew: Adverse event0000502
Withdrew: Pregnancy0000001
Period 4 (Safety Follow-Up)
Participant flow — Period 4 (Safety Follow-Up)
MilestonePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)VAY736 - 150 mgVAY736 300 mg - PlaceboVAY736 300 mg - VAY736 300 mg
Started247474462220
Completed241431422020
Not completed0643420
Withdrew: Lack of efficacy0100000
Withdrew: Lost to follow-up0000100
Withdrew: New therapy for indication0000100
Withdrew: Withdrawal of informed consent0312000
Withdrew: Withdrawal by subject0231220

Outcome measures

PrimaryLeast Squares Mean Change From Baseline in ESSDAI Score at Week 24

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in ESSDAI Score at Week 24
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Least Squares Mean Change From Baseline in ESSDAI Score at Week 24-6.39 ± 0.808-5.64 ± 0.850-6.93 ± 0.836-8.30 ± 0.828
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.5161 · Least squares mean difference: 0.75 · 95% CI -1.52 to 3.02Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.6332 · Least squares mean difference: -0.55 · 95% CI -2.80 to 1.71Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.0921 · Least squares mean difference: -1.92 · 95% CI -4.15 to 0.32Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
SecondaryLeast Squares Mean Change From Baseline in ESSDAI Score at Weeks 4, 8, 12, and 16

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in ESSDAI Score at Weeks 4, 8, 12, and 16
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Week 4-3.73 ± 0.626-2.28 ± 0.661-3.37 ± 0.638-4.53 ± 0.651
Week 8-4.13 ± 0.704-4.65 ± 0.733-4.73 ± 0.720-6.38 ± 0.717
Week 12-5.45 ± 0.721-4.89 ± 0.762-5.69 ± 0.739-6.64 ± 0.739
Week 16-6.08 ± 0.818-5.67 ± 0.852-6.17 ± 0.835-6.99 ± 0.836
SecondaryLeast Squares Mean Change From Baseline in ESSPRI Score at Week 24

The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in ESSPRI Score at Week 24
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Least Squares Mean Change From Baseline in ESSPRI Score at Week 24-1.71 ± 0.288-1.39 ± 0.304-1.70 ± 0.301-1.77 ± 0.295
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.4457 · Least squares mean difference: 0.32 · 95% CI -0.50 to 1.13Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.301 · Least square mean difference: 0.01 · 95% CI -0.79 to 0.82Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.8858 · Least square mean difference: -0.06 · 95% CI -0.86 to 0.74Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
SecondaryLeast Squares Mean Change From Baseline in ESSPRI Score at Weeks 4, 8, 12 and 16

The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in ESSPRI Score at Weeks 4, 8, 12 and 16
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Week 4-0.54 ± 0.236-0.67 ± 0.247-0.80 ± 0.241-0.88 ± 0.242
Week 8-0.94 ± 0.242-0.84 ± 0.255-1.06 ± 0.251-1.8 ± 0.248
Week 12-1.42 ± 0.265-1.36 ± 0.279-1.44 ± 0.273-1.23 ± 0.270
Week 16-1.77 ± 0.263-1.27 ± 0.275-1.55 ± 0.271-1.55 ± 0.270
SecondaryLeast Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks

The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks9.05 ± 1.4047.12 ± 1.5026.48 ± 1.5189.36 ± 1.436
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.3424 · Least squares mean difference: -1.93 · 95% CI -5.93 to 2.07Confidence intervals and p-values are derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.2092 · Least squares mean difference: -2.56 · 95% CI -6.58 to 1.45Confidence intervals and p-values are derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.8740 · Least squares mean difference: 0.31 · 95% CI -3.58 to 4.20Confidence intervals and p-values are derived from a mixed model for repeated measures (MMRM)
SecondaryLeast Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score at Weeks 4, 8, 12 and 16

The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.

Time frame:
Baseline, Weeks 4, 8, 12 and 16
Reported as:
Mean · Scores on a scale
Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score at Weeks 4, 8, 12 and 16
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Week 43.78 ± 1.1756.32 ± 1.2393.12 ± 1.2293.39 ± 1.203
Week 85.49 ± 1.2226.36 ± 1.2973.93 ± 1.3035.98 ± 1.250
Week 126.25 ± 1.3498.17 ± 1.4295.73 ± 1.4276.05 ± 1.374
Week 168.56 ± 1.2847.09 ± 1.3576.86 ± 1.3598.30 ± 1.318
SecondaryLeast Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) Over 24 Weeks

The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) Over 24 Weeks
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Mental Component Score4.63 ± 1.2593.61 ± 1.3505.31 ± 1.3675.63 ± 1.286
Physical Component Score3.66 ± 0.9524.79 ± 1.0192.66 ± 1.0265.50 ± 0.972
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.5768 · Least squares mean difference: -1.02 · 95% CI -4.61 to 2.57Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.7113 · Least squares mean difference: 0.68 · 95% CI -2.93 to 4.28Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.5722 · Least squares mean difference: 1.00 · 95% CI -2.49 to 4.48Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.4138 · Least squares mean difference: 1.84 · 95% CI -1.59 to 3.83Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.4663 · Least squares mean difference: -1.00 · 95% CI -3.72 to 1.71Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.1694 · Least squares mean difference: 1.84 · 95% CI -0.79 to 4.47Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
SecondaryLeast Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) at Weeks 4, 8, 12 and 16

The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).

Time frame:
Baseline, Weeks 4, 8, 12 and 16
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) at Weeks 4, 8, 12 and 16
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Week 4 - Mental Component Score0.49 ± 1.0911.89 ± 1.1512.46 ± 1.1492.18 ± 1.116
Week 8 - Mental Component Score2.65 ± 2.2673.80 ± 1.3414.65 ± 1.3633.35 ± 1.294
Week 12 - Mental Component Score2.89 ± 1.1885.42 ± 1.2643.94 ± 1.2654.59 ± 1.207
Week 16 - Mental Component Score4.60 ± 1.2143.00 ± 1.2815.57 ± 1.2915.46 ± 1.247
Week 4 - Physical Component Score3.35 ± 0.8443.94 ± 0.8891.14 ± 0.8781.98 ± 0.863
Week 8 - Physical Component Score3.83 ± 0.8944.56 ± 0.9493.48 ± 0.9413.47 ± 0.909
Week 12 - Physical Component Score3.83 ± 0.8944.56 ± 0.9493.48 ± 0.9413.47 ± 0.909
Week 16 - Physical Component Score4.72 ± 0.9684.67 ± 1.0203.32 ± 1.0214.57 ± 0.993
SecondaryLeast Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks

Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.

Time frame:
Baseline, 24 weeks
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks-23.64 ± 2.601-27.81 ± 2.751-28.13 ± 2.700-31.99 ± 2.630
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.2671 · Least squares mean difference: -4.17 · 95% CI -11.56 to 3.22Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.2248 · Least squares mean difference: -4.49 · 95% CI -11.78 to 2.79Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.0224 · Least squares mean difference: -8.36 · 95% CI -15.51 to -1.20Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
SecondaryLeast Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) at Weeks 4, 8, 12 and 16

Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.

Time frame:
Baseline, Weeks 4, 8, 12 and 16
Reported as:
Least squares mean · Scores on a scale
Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) at Weeks 4, 8, 12 and 16
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Week 4-12.49 ± 2.327-10.50 ± 2.445-12.38 ± 2.361-18.67 ± 2.367
Week 8-18.54 ± 2.239-16.53 ± 2.338-22.12 ± 2.374-24.85 ± 2.289
Week 12-21.01 ± 2.299-20.72 ± 2.413-25.35 ± 2.341-27.25 ± 2.305
Week 16-19.44 ± 2.572-24.49 ± 2.687-24.77 ± 2.676-25.77 ± 2.633
SecondaryPatient's Global Assessment (PaGA) Score at Weeks 4, 8, 12, 16 and 24

The PaGA of disease activity was performed using a 100 mm Visual Analog Scale (VAS) ranging from 0 (no disease activity) to 100 (maximal disease activity), in response to the question "Considering all the ways Sjögren's syndrome affects you, please draw a line on the scale to indicate how well you are doing today". A negative change from baseline is a favourable outcome.

Time frame:
Weeks 4, 8, 12, 16 and 24
Reported as:
Least squares mean · Scores on a scale
Patient's Global Assessment (PaGA) Score at Weeks 4, 8, 12, 16 and 24
Scores on a scalePlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Week 4-9.42 ± 2.850-10.02 ± 2.992-5.96 ± 2.969-8.96 ± 2.906
Week 8-9.74 ± 3.035-11.48 ± 3.214-8.70 ± 3.271-15.27 ± 3.091
Week 12-11.45 ± 3.064-17.51 ± 3.244-11.73 ± 3.234-13.57 ± 3.105
Week 16-16.26 ± 3.194-17.56 ± 3.361-14.86 ± 3.375-15.78 ± 3.271
Week 24-15.11 ± 3.405-12.83 ± 3.648-11.85 ± 3.704-19.87 ± 3.470
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.6457 · Least squares mean difference: 2.27 · 95% CI -7.46 to 12.00Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.5132 · Least squares mean difference: 3.26 · 95% CI -6.55 to 13.06Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 95 · Least squares mean difference: -4.77 · 95% CI -14.21 to 4.68Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
SecondaryLeast Squares Mean Change From Baseline in Salivary Flow Rate at Week 24

Change from baseline in salivary flow rate (unstimulated and stimulated) at 24 weeks as compared to placebo. Unstimulated saliva is a mix of serous and mucous secretions coming primarily from the submandibular and minor salivary glands. The parotid gland produces the largest volume of stimulated saliva. Stimulated saliva accounts for 80-90% of daily salivary production.

Time frame:
Baseline, 24 weeks
Reported as:
Least squares mean · mL/min
Least Squares Mean Change From Baseline in Salivary Flow Rate at Week 24
mL/minPlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)
Stimulated0.05 ± 0.0670.16 ± 0.0740.18 ± 0.0710.25 ± 0.98
Unstimulated0.00 ± 0.0300.01 ± 0.034-0.00 ± 0.032-0.01 ± 0.031
Statistical analysis
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.2710 · Least squares mean difference: 0.11 · 95% CI -0.08 to 0.30Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.1618 · Least squares mean difference: 0.13 · 95% CI -0.05 to 0.32Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.0374 · Least squares mean difference: 0.20 · 95% CI 0.01 to 0.38Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 5 mg (Up to Week 24) · Mixed Models Analysis · p = 0.9559 · Least squares mean difference: 0.00 · 95% CI -0.09 to 0.09Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 50 mg (Up to Week 24) · Mixed Models Analysis · p = 0.9290 · Least squares mean difference: -0.00 · 95% CI -0.09 to 0.08Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
  • Placebo (Up to Week 24) vs VAY736 - 300 mg (Up to Week 24) · Mixed Models Analysis · p = 0.7276 · Least squares mean difference: -0.01 · 95% CI -0.10 to 0.07Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)
SecondaryPercent Change From Baseline in Whole Blood CD19+ B-cell Counts.

B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.

Time frame:
Baseline, Week 24, Week 28
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Whole Blood CD19+ B-cell Counts.
Percent changeVAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)Placebo - VAY150 mgVAY736 300 mg - PlaceboVAY736 300 mg - VAY736 300 mg
Week 24-88.00 ± 5.784-99.07 ± 5.8123.29 ± 5.674-103.0 ± 8.198-94.20 ± 8.098
Week 28——-97.06 ± 5.732-105.3 ± 9.145-91.80 ± 8.272
SecondaryKaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts

B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.

Time frame:
Up to two years from last dose patient received.
Reported as:
Median · months
Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts
monthsVAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)Placebo - VAY150 mgVAY736 300 mg - PlaceboVAY736 300 mg - VAY736 300 mg
Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts3.8 (2.7 to 5.2)4.8 (4.7 to 6.6)6.8 (5.0 to 9.2)8.4 (6.8 to 9.1)6.5 (4.9 to 7.5)
SecondaryPeak Serum Concentration of VAY736

Pharmacokinetic Concentrations This outcome only applies to patients who received at least one dose of VAY739 (so not applicable to placebo)

Time frame:
baseline to week 24, then week 28
Reported as:
Mean · ug/mL
Peak Serum Concentration of VAY736
ug/mLVAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)VAY736 300 mg - PlaceboVAY736 300 mg - VAY736 300 mg
Peak Serum Concentration of VAY7360.0747 ± 0.2030.475 ± 0.3801.46 ± 0.5962.15 ± 1.471.94 ± 1.53

Adverse events

Collected over From first dose of study drug until end of follow-up period, up to approximately 3 years (max duration of follow-up was 2 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Up to Week 24)0/49 (0%)3/49 (6.1%)33/49 (67.3%)
VAY736 - 5 mg (Up to Week 24)0/47 (0%)0/47 (0%)40/47 (85.1%)
VAY736 - 50 mg (Up to Week 24)0/47 (0%)1/47 (2.1%)34/47 (72.3%)
VAY736 - 300 mg (Up to Week 24)0/47 (0%)2/47 (4.3%)41/47 (87.2%)
Any VAY736 (Up to Week 24)0/141 (0%)3/141 (2.1%)115/141 (81.6%)
ALL (Up to Week 24)0/190 (0%)6/190 (3.2%)148/190 (77.9%)
VAY736 - 5 mg 24 Weeks (Periods 2 and 4)0/47 (0%)3/47 (6.4%)41/47 (87.2%)
VAY736 - 50 mg 24 Weeks (Periods 2 and 4)0/47 (0%)7/47 (14.9%)37/47 (78.7%)
VAY736 - 150 mg 28 Weeks (Periods 3 and 4)0/47 (0%)9/47 (19.1%)41/47 (87.2%)
VAY736 - 300 mg 24 Weeks (Entire Study)0/26 (0%)5/26 (19.2%)24/26 (92.3%)
VAY736 - 300 mg 52 Weeks (Entire Study)0/21 (0%)5/21 (23.8%)20/21 (95.2%)
Any VAY736 - 300 mg (Periods 2, 3 and 4)0/47 (0%)10/47 (21.3%)44/47 (93.6%)
Any VAY736 (Periods 2, 3 and 4)0/188 (0%)29/188 (15.4%)163/188 (86.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)Any VAY736 (Up to Week 24)ALL (Up to Week 24)VAY736 - 5 mg 24 Weeks (Periods 2 and 4)VAY736 - 50 mg 24 Weeks (Periods 2 and 4)VAY736 - 150 mg 28 Weeks (Periods 3 and 4)VAY736 - 300 mg 24 Weeks (Entire Study)VAY736 - 300 mg 52 Weeks (Entire Study)Any VAY736 - 300 mg (Periods 2, 3 and 4)Any VAY736 (Periods 2, 3 and 4)
CholelithiasisHepatobiliary disorders0/490/470/471/471/1411/1900/470/470/470/262/212/472/188
PneumoniaInfections and infestations1/490/470/470/470/1411/1900/470/471/470/261/211/472/188
Traumatic fractureInjury, poisoning and procedural complications0/490/470/470/470/1410/1900/470/470/470/261/211/471/188
MigraineNervous system disorders0/490/470/470/470/1410/1900/470/470/470/261/211/471/188
AnaemiaBlood and lymphatic system disorders0/490/470/470/470/1410/1900/470/470/471/260/211/471/188
Deafness neurosensoryEar and labyrinth disorders0/490/470/471/471/1411/1900/470/470/471/260/211/471/188
COVID-19Infections and infestations0/490/470/470/470/1410/1900/470/470/471/260/211/471/188
COVID-19 pneumoniaInfections and infestations0/490/470/470/470/1410/1900/470/470/471/260/211/471/188
Weight decreasedInvestigations0/490/470/470/470/1410/1900/470/470/471/260/211/471/188
Device breakageProduct Issues0/490/470/470/470/1410/1900/470/470/471/260/211/471/188
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlacebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)Any VAY736 (Up to Week 24)ALL (Up to Week 24)VAY736 - 5 mg 24 Weeks (Periods 2 and 4)VAY736 - 50 mg 24 Weeks (Periods 2 and 4)VAY736 - 150 mg 28 Weeks (Periods 3 and 4)VAY736 - 300 mg 24 Weeks (Entire Study)VAY736 - 300 mg 52 Weeks (Entire Study)Any VAY736 - 300 mg (Periods 2, 3 and 4)Any VAY736 (Periods 2, 3 and 4)
Injection site reactionGeneral disorders2/494/479/4726/4739/14141/1904/479/4717/4713/2614/2127/4757/188
Upper respiratory tract infectionInfections and infestations4/494/475/472/4711/14115/1907/479/477/478/262/2110/4733/188
NasopharyngitisInfections and infestations5/494/472/477/4713/14118/1907/474/4711/475/264/219/4731/188
Urinary tract infectionInfections and infestations4/496/472/470/478/14112/1909/475/477/472/263/215/4726/188
LeukopeniaBlood and lymphatic system disorders2/493/472/476/4711/14113/1903/472/474/472/264/216/4715/188
DiarrhoeaGastrointestinal disorders4/493/472/473/478/14112/1903/473/472/473/264/217/4715/188
Back painMusculoskeletal and connective tissue disorders3/491/474/472/477/14110/1903/474/476/474/262/216/4719/188
HeadacheNervous system disorders7/494/474/474/4712/14119/1905/475/474/474/262/216/4720/188
SinusitisInfections and infestations4/494/472/470/476/14110/1905/473/477/472/261/213/4718/188
Injection related reactionInjury, poisoning and procedural complications2/496/475/474/4715/14117/1906/475/477/472/262/214/4722/188

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)Total
Mean47.9 ± 12.4452.5 ± 13.6451.0 ± 11.1249.1 ± 15.4150.9 ± 13.48
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)Total
Female47464146180
Male216110
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (Up to Week 24)VAY736 - 5 mg (Up to Week 24)VAY736 - 50 mg (Up to Week 24)VAY736 - 300 mg (Up to Week 24)Total
Asian4310522
Black or African American01001
White44423742165
Unknown11002
08

Study locations

56 sites
  • Integral Rheumatology and Immunology Specialists IRIS
    Plantation, Florida 33324, United States
  • Indiana Univ School of Dentistry
    Indianapolis, Indiana 46202, United States
  • The John Hopkins Jerome L Greene Sjogren
    Baltimore, Maryland 21224, United States
  • Tufts School of Dental Medicine
    Boston, Massachusetts 02111, United States
  • AAIR Research Center
    Rochester, New York 14618, United States
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Advanced Rheumatology and Arthritis Wellness Center
    Wexford, Pennsylvania 15090, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • First Outpatient Research Unit
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, Buenos Aires C1055AAF, Argentina
  • Novartis Investigative Site
    Caba, 1117, Argentina
  • Novartis Investigative Site
    Cordoba, 5000, Argentina
  • Novartis Investigative Site
    Cordoba, X5016KEH, Argentina
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Santiago, 7500710, Chile
  • Novartis Investigative Site
    Santiago, 8207257, Chile
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
  • Novartis Investigative Site
    Budapest, H-1097, Hungary
  • Novartis Investigative Site
    Szeged, 6720, Hungary
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 457 8510, Japan
  • Novartis Investigative Site
    Sasebo-city, Nagasaki 857-1165, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160 8582, Japan
  • Novartis Investigative Site
    Rotterdam, Zuid Holland 3015 GD, Netherlands
  • Novartis Investigative Site
    Lublin, 20-954, Poland
  • Novartis Investigative Site
    Almada, 2801 951, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-034, Portugal
  • Novartis Investigative Site
    Lisboa, 1649 035, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Brasov, 500283, Romania
  • Novartis Investigative Site
    Cluj Napoca, 400006, Romania
  • Novartis Investigative Site
    Ekaterinburg, 620028, Russian Federation
  • Novartis Investigative Site
    Moscow, 115522, Russian Federation
  • Novartis Investigative Site
    Orenburg, 460000, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 195257, Russian Federation
  • Novartis Investigative Site
    Vigo, Pontevedra 36200, Spain
  • Novartis Investigative Site
    La Laguna, Santa Cruz De Tenerife 38320, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Kaohsiung, 81346, Taiwan
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Taipei, 11490, Taiwan
  • Novartis Investigative Site
    Birmingham, B15 2TH, United Kingdom
  • Novartis Investigative Site
    Liverpool, L9 7AL, United Kingdom
  • Novartis Investigative Site
    Southend, SSO 0RY, United Kingdom
09

References and documents

Publications

  • Bowman SJ, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Erratum In: Lancet. 2025 Mar 29;405(10484):1056. doi: 10.1016/S0140-6736(25)00560-4. PubMed 34861168 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jun 2020, 36 months.

Results were first posted in Oct 2024, 4 years 3 months after primary completion. A results delay was requested in Jul 2020.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2016
First posted
Nov 15, 2016
StartActual
Jun 27, 2017
Primary completionActual
Jun 30, 2020
CompletionActual
Sep 23, 2021
Results delay requested
Jul 16, 2020
Results first posted
Oct 29, 2024
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02962895
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Jun 27, 2017
Primary completion
Jun 30, 2020
Completion
Sep 23, 2021
Results posted
Oct 29, 2024
Last update
Jan 7, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion